Poster presented at SITC 2024, Houston
We partner with academic institutions to evaluate our ex vivo platform. These efforts include research collaborations and ongoing clinical trials. Here, we invite you to dive deeper into the data behind our platform.
Poster presented at SITC 2024, Houston
Poster presented at SITC 2024, Houston
Consistent with clinical studies and real-world data, the Elephas platform detects an enrichment in cytokine response to αPD-1 treatment in human LTFs from biomarker-positive specimens.
Paper published in Journal of Biomedical Optics
We have developed and fully characterized a label-free imaging assay of cell viability based on multiphoton fluorescence lifetime imaging microscopy that leaves tissues intact and viable for repeated assessment of specimens over time, as well as downstream evaluation with other Elephas platform assays.
Paper published in Biomedical Optics Express
We demonstrate that dynamic optical coherence microscopy, a technical component of the Elephas platform, can distinguish live cells from dead cells in murine syngeneic tumors.
Poster presented at AACR 2024, San Diego
The Elephas platform can be used to assess immune checkpoint inhibitor response in clinically relevant core needle biopsies.
Poster presented at SITC 2023, San Diego
The Elephas platform can simultaneously assess activation of T cells and cytotoxic killing of tumor cells in response to immune checkpoint inhibitors.
Poster presented at AACR 2023, Orlando
Using nondestructive, label-free multiphoton microscopy, the Elephas platform accurately predicts live/dead status of live tumor fragments (LTFs) and can assess tumors longitudinally.
Poster presented at SITC 2022, Boston
The Elephas platform addresses heterogeneity of tumors and creates homogenous treatment groups which can receive adoptive T cells, indicating CAR T-cell therapy can be assessed on the platform.
Poster presented at AACR 2022, New Orleans
LTFs are viable, maintain motility of T cells and respond to checkpoint inhibitors by increasing cell surface marker expression and cytokine production, supporting the maintenance of the tumor microenvironment in our platform.
Poster presented at AACR 2022, New Orleans
The Elephas platform leverages nondestructive multiphoton label-free imaging to differentiate between live and dead cells in LTFs.
Poster presented at AACR 2022, New Orleans
The Elephas platform can track the motility of T cells and can distinguish T cells from tumor associated macrophages.
Elephas is conducting three observational clinical trials. The primary objective of these studies is to determine the ex-vivo predictive accuracy of the Elephas platform across a variety of solid tumors.
Study endpoints:
Measured per RECIST v1.1 and iRECIST
Primary endpoint: Sensitivity in predicting clinical response to immunotherapy
Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform
Tumor types:
Non-small cell lung cancer
Setting:
Metastatic & recurrent
Complete study details: NCT05478538Observational Basket Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform
Tumor types:
Bladder cancerColorectal cancerEndometrial cancerHead & neck cancerKidney cancerLiver cancerMelanomaNon-small cell lung cancerTriple negative breast cancer
Setting:
Metastatic & recurrentAdvanced
Complete study details: NCT05520099Mayo Clinic MC230901: Observational Basket Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform
Tumor types:
Bladder cancerColorectal cancerEndometrial cancerHead & neck cancerKidney cancerLiver cancerMelanomaNon-small cell lung cancerTriple negative breast cancer
Setting:
Metastatic & recurrentAdvancedNeoadjuvantAdjuvant
Complete study details: NCT0634962These trials will provide an opportunity to demonstrate correlation between ex vivo and clinical response to immunotherapy regimenS.
Hospitals and academic research centers within the US provide consented patient specimens.
If you are a physician or researcher, contact us to learn more.